Physician profile
David R Chen
NPI 1093941510
$9,900.38
in general payments reported to CMS, 2019-2025
29 companies · $870 in 2025
The $870 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $662 · 2021: $1,126 · 2022: $2,040 · 2023: $1,978 · 2024: $2,162 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,162.53 | 2019-2025 | Enbrel, Evenity, Prolia |
| Ucb, INC. | $1,313.52 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $963.78 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $941.55 | 2019-2025 | |
| Abbvie INC. | $936.34 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $508.91 | 2019-2024 | |
| Genentech USA, INC. | $377.10 | 2019-2025 | Actemra |
| Glaxosmithkline, LLC. | $293.78 | 2019-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $291.32 | 2021-2024 | Saphnelo |
| Pacira Therapeutics, INC. | $268.24 | 2019-2021 | |
| Radius Health, INC. | $263.73 | 2019-2023 | Tymlos |
| Genzyme Corporation | $234.22 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $220.53 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.09 | 2021-2024 | Cyltezo |
| Ani Pharmaceuticals, INC. | $144.23 | 2022-2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $132.61 | 2021-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $126.24 | 2020-2023 | Strensiq |
| Depuy Synthes Sales INC. | $87.62 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $84.12 | 2020-2022 | |
| Sobi, INC | $82.88 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $64.07 | 2023-2024 | Idacio, Sodium Chloride, Tyenne |
| Hikma Pharmaceuticals USA | $60.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $53.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.30 | 2020-2024 | Orencia |
| Kiniksa Pharmaceuticals, LTD. | $22.63 | 2022 | |
| Fidia Pharma USA INC. | $21.90 | 2020 | |
| Organon LLC | $21.18 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.34 | 2019 | |
| Horizon Therapeutics Plc | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.